These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
329 related items for PubMed ID: 20026805
1. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M, Petersdorf S, Shami PJ, Yeager AM, Eckert S, Abichandani R, Faderl S. J Clin Oncol; 2010 Feb 01; 28(4):549-55. PubMed ID: 20026805 [Abstract] [Full Text] [Related]
5. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial). Willemze R, Suciu S, Muus P, Halkes CJ, Meloni G, Meert L, Karrasch M, Rapion J, Vignetti M, Amadori S, de Witte T, Marie JP. Ann Hematol; 2014 Jun 01; 93(6):965-75. PubMed ID: 24682421 [Abstract] [Full Text] [Related]
15. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors. Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X. Ann Hematol; 2003 Nov 01; 82(11):684-90. PubMed ID: 12928754 [Abstract] [Full Text] [Related]
18. Prognostic factors for therapy-related acute myeloid leukaemia (t-AML)--a single centre experience. Suvajdžić N, Cvetković Z, Dorđević V, Kraguljac-Kurtović N, Stanisavljević D, Bogdanović A, Djunić I, Colović N, Vidović A, Elezović I, Tomin D. Biomed Pharmacother; 2012 Jun 01; 66(4):285-92. PubMed ID: 22401928 [Abstract] [Full Text] [Related]